The efficacy of target inhibition was established by using the plasma inhibitory activity (PIA) assay for FLT3 [71]. analyzed [20, 21]. FL works in synergy with additional cytokines to market hematopoietic precursor development, and targeted disruption of either FLT3 or FL in mice qualified prospects to a decrease in hematopoietic Continue Reading